Method for the isolation of antibodies with functional activity against cell surface targets

“用于分离具有针对细胞表面靶标的功能活性的抗体的方法” 摘要 我们已经推导出一种分离针对细胞表面受体的功能性mAb的方法，所述细胞表面受体分别 激动剂、拮抗剂和部分激动剂。我们称之为定向配体结合（DLB）的方法。 在DLB的第一次迭代（DLB 1）中，我们已经成功地将其用于肽和蛋白质配体。使用 DLB 1这些配体被遗传地整合到DLB 1的互补决定区（CDR）中。 合适的噬菌体展示scFv文库。本质上，DLB是一种引导或偏置初始结合的手段， 的消减的（以去除非特异性和不相关的结合）噬菌体展示的Ab文库朝向靶 通过将受体的配体或抑制剂掺入Ab文库本身，来扩增细胞表面受体结合位点。 然后依靠增加的结合能力，通过单个mAb的CDR和 共价连接的配体瞬时稳定Ab：：受体复合物以承受增加的 用于除去任何弱结合物的噬菌体生物淘选洗涤循环的严格性。在DLB 1中 方法，我们将配体遗传编码到Ab的CDR中。但这限制了我们对肽和蛋白质的研究 配体。我们现在想要将用于配体的酶促缀合的DLB方法应用于一种新的酶促缀合方法中。 互补文库的适当修饰的CDR。我们将这种新方法称为DLB2.0。的 DLB2.0方法的显著优点有几个方面，包括：（1）可以使用相同的文库 用于许多筛选，和（2）用于检测来自DLB2.0的mAb的方法， 配体是微不足道的;只需在任何筛选之前省略配体连接步骤。该研究使用了几个 GPCR靶标作为模型，基于细胞的报告基因测定中的功能性作为应用。关于 在商业应用中，我们主要关注的是方法。我们的目标 选择开发的方法，在某些情况下，没有特殊的商业价值。当 DLB2.0生成适当的IgG，我们打算与强大的学术合作伙伴和合作， 通过向制药和生物技术公司提供IgG克隆和/或纯化的IgG蛋白质 这样他们就可以进行结构和生物学研究， 我们开发的mAb在Abbratech打算提供定制服务的商业实体 （制药和生物技术公司）使用从这项工作中获得的数据，包括任何 协作结果，作为DLB 2.0的强大功能的演示。

“Method for the isolation of antibodies with functional activity against cell surface targets” ABSTRACT We have derived a method for isolating functional mAbs against cell surface receptors that are separately either agonists, antagonists, and partial agonists. We termed the method Directed Ligand Binding (DLB). And in DLB’s first iteration (DLB1) we have successfully used it for peptide- and protein ligands. Using DLB1 these ligands were genetically incorporated into the complementarity determining region (CDR) of an appropriate phage display scFv library. At its essence DLB is a means to direct or bias the initial binding of a subtracted (to remove non-specific- and irrelevant binding) phage displayed Ab library toward a target cell surface receptor binding site by incorporating that receptor’s ligand or inhibitor into the Ab library itself. And then rely on the increased binding ability, via the interaction of both an individual mAb’s CDRs plus the covalently attached ligand to transiently stabilize the Ab::receptor complex to withstand the increasing stringency of the phage biopanning washing cycles used to remove any weak binders. In the DLB1 method, we genetically encoded the ligand into the Ab’s CDR. But that limited us to peptide and protein ligands. We now want to apply the DLB method for the enzymatic conjugation of ligands into an appropriately modified CDR of a complementing library. We refer to this new method as DLB2.0. The significant advantages of the DLB2.0 method are several fold, including: (1) the same library can be used for many screens, and (2) the means for testing mAbs derived from DLB2.0 with and without attached ligand is trivial; just omit the ligand attachment step before any screen. The proposed study uses several GPCR targets as the model and functionality in a cell-based reporter assay as the application. Regarding the commercial application, we are mainly focused on the method. It is true that the targets we have chosen to develop the method, in some cases, do not have exceptional commercial value. When the DLB2.0 generates appropriate IgGs we intend to partner and collaborate with strong academic, and pharmaceutical- and biotech companies by providing them with the IgG clones and/or purified IgG proteins so that they can perform the structural and biological studies needed to both better understand and utilize the mAbs we develop. At Abbratech intend to provide custom services to commercial entities (Pharmaceutical and Biotechnology companies) using the data obtained from this work, including any collaborative results, as a demonstration of the power of DLB2.0.